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ABSTRACT
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease that is
characterized by progressive loss of memory and cognitive function. The causative
factors of this disease include modifications in neuronal cell metabolism, such as the
progression of neurotic injury by amyloid beta (Aβ), and tau tangle deposition in the
brain. Recent studies show that brain atrophy and other pathologic conditions are
responsible for dementia in older individuals (80 years of age or older). Nonpharmacological interventions may have a role in both the prevention and slowing
disease progression in AD. The role of exercise training in disease prevention has been
evaluated in large epidemiological studies even though much less is known about the
potential benefit of exercise training in patients already diagnosed with AD. Several
studies in transgenic mouse models of AD suggest exercise training reduces soluble and
insoluble Aβ levels in the brain. This study assessed the effectiveness of long-term
exercise training (12-months) in an AD transgenic mouse model, Tg2576. Amyloid
plaque levels and behavioral profile of mice were evaluated after 12 months of training.
Mice that received daily exercise training demonstrated beneficial behavioral profile and
reduced plaque counts in a dose-dependent manner.
KEYWORDS: Alzheimer’s disease, exercise training, cognition, Aβ plaques, Tg2576
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INTRODUCTION

Neurodegenerative Diseases
Neurodegenerative diseases are characterized by selective and symmetric loss of
neurons in motor, sensory, and cognitive systems (Gorman, 2008). Description of the
patterns of cell loss and the identification of disease-specific cellular markers have aided
in nosologic classification. Senile plaques, neurofibrillary tangles, neuronal loss, and
acetylcholine deficiency define Alzheimer’s disease (AD), depletion of dopamine
characterizes Parkinson's disease (PD), cellular inclusions and swollen motor axons are
found in amyotrophic lateral sclerosis (ALS), and γ-aminobutyric acid containing
neurons of the neostriatum are lost in Huntington's disease (HD) (Martin, 1999).
In some neurological diseases such as AD, genes have been found which lead to a
clinical and pathological syndrome, with only variations in the age at onset and the rate
of progression. In other disorders such as Downs’s syndrome, errors in DNA replication
resulting in an increased number of trinucleotide repeats are associated with selective
patterns of neurodegeneration (Martin, 1999). In these disorders, heterozygotes are as
severely affected as homozygotes, suggesting that the biochemical change caused by the
mutation results in toxicity to the cell (Martin, 1999). In contrast, in autosomal recessive
disorders such as Friedreich's ataxia, the manifestations of the disease are caused by a
cellular loss of function due to the failure of protein production. These conditions are
most likely caused by abnormalities in the transport, degradation, and aggregation of
proteins that lead to cell-specific changes and ultimately to neuronal death, probably by
apoptosis (Mattson, 2000; De Strooper, 2010).
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The identification of specific genetic and environmental factors responsible for
these diseases has strengthened evidence for a shared pathway of neuronal death, which
involves oxidative stress, stressed calcium homeostasis, mitochondrial dysfunction and
activation of cysteine proteases called caspases (Brady and Morfini, 2010). These
cascades are counteracted by survival signals, which suppress oxygen radicals and
stabilize calcium homeostasis and mitochondrial function. With the identification of
mechanisms that either promote or prevent neuronal apoptosis, new approaches need to
be developed for preventing and treating neurodegenerative disorders such as AD (Li et
al., 2015).
Overview of AD
In 1901, Dr. Alois Alzheimer’s patient, Auguste Deter had strange behavioral
symptoms such as short-term memory loss. In April 1906, after her death, Alzheimer
along with two Italian physicians used Nissl staining techniques to identify amyloid
plaques and neurofibrillary tangles in her brain. Later in November 1906, Dr.
Alzheimer’s speech at the physicians’ conference in Germany about the pathology and
clinical symptoms of pre-senile dementia was groundbreaking.
AD usually begins in the seventh to ninth decade of life, but an early-onset
familial form is now well recognized where disease symptoms are manifested in the fifth
and sixth decades (Thorvaldsson et al., 2011). The disease affects over 4 million people
in the United States, resulting in over 100,000 deaths per year. The risk of AD rises
sharply with advancing age, and as life expectancy increases, the effect of the disease will
also increase (Price et al., 2009).
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Brain changes associated with AD lead to growing trouble with memory, thinking
and reasoning, making judgments and decisions, planning and performing familiar tasks,
vision loss, and changes in personality and behavior (Shankar et al., 2008). Symptoms of
AD progressively deteriorate over time. In many instances, AD patients start developing
symptoms earlier but only receive an official diagnosis years later. Post diagnosis patients
enter the second stage of the disease where they develop mild cognitive impairment
which will last two to ten years. Alzheimer’s dementia occurs during the final stages
where there is severe damage and this is the most extreme form of the disease. The
similarity of pathologic findings in the different AD groups provides evidence for a
common pathophysiological pathway in AD (Lippa et al., 1996). With respect to the
severity of changes and location of tangle-bearing neurons, the disease progresses in six
stages: transentorhinal stages I–II: clinically silent cases; limbic stages III–IV: incipient
AD; neocortical stages V–VI: fully developed AD (Sperling et al., 2011).
Pathology of AD
The neuropathological features of neurofibrillary tangles and senile plaques
described by Dr. Alzheimer, in 1907, result in the progressive loss of memory and
cognitive function (Harman, 2006). These modifications are indications of the cause of
AD, especially neuronal cell metabolism in the form of neuritic injury, and neuronal cell
death affecting the brain (Serrano-Pozo et al., 2011).
Recent studies show that brain atrophy and other pathologic conditions are
responsible for dementia in the oldest persons (80 years of age or older). AD may be
primarily a disorder of synaptic failure where hippocampal synapses begin to decline in
patients with mild cognitive impairment in whom residual synaptic outlines show
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compensatory increases in size. As the disease progresses synapses are disproportionately
fewer relative to neurons (Loo et al., 1993). The core symptoms of AD include cognitive
impairment, decline in the ability to perform daily activities, and manifestation of
behavioral and psychological symptoms of dementia (BPSD).
There is progressive brain cell death that occurs over a course of time in AD and
the total brain size shrinks, where the tissue has progressively fewer nerve cells and
connections. While these cannot be observed in the brains of living people affected by
AD, postmortem results show tiny inclusions in the nerve tissue called plaques. Cerebral
plaques that are burdened with Aβ, dystrophic neuritis in neocortex, and neurofibrillary
tangles in medial temporal-lobe structures are important pathological features of AD
(Christen, 2000) (Figure 1).

Figure 1. PET image comparison of normal versus AD brain. Positron Emission
Tomography (PET) scan images of normal brain and AD brains with amyloid plaques
(Credit: University of Pittsburgh, PET Amyloid Imaging Group).
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Amyloid Cascade Hypothesis of AD
There currently exist several hypotheses concerning the development and
progression of AD. The most studied and widely accepted is the amyloid cascade
hypothesis. This hypothesis suggests that the deposition of a protein, the amyloid-beta
(Aβ) peptide in the brain, is a crucial step that ultimately leads to AD (Saunders et al.,
1993; Lippa et al., 1996; Sperling et al., 2011). The aggregation of Aβ into toxic
oligomers and eventually plaque later in life is directly related to soluble Aβ peptide
concentrations in the brain during midlife (Bero et al., 2011). Soluble Aβ concentration in
the brain depend on the relative rates of which the peptide is produced and cleared. The
aggregation of Aβ into oligomers and eventually plaque is shown in Figure 2.

Figure 2. Plaque formation. Soluble Aβ aggregates into toxic soluble oligomers, then
insoluble fibrils, and finally into plaque in the extracellular space in the brain (Image
courtesy of the National Institute on Aging/National Institute of Health).
5

Aβ Production. Aβ is produced when two different enzymes cleave the 771
amino acid amyloid precursor protein (APP) which is crucial for neuronal development
and synaptic connection (Mattson, 2000). The enzymes beta-secretase and gammasecretase sequentially cleave APP producing Aβ, which can be 38, 40 or 43 amino acids
long (Fig 1) (Querfurth and LaFerla, 2006). The Aβ is 42 amino acid form is more
hydrophobic than the shorter forms and is more likely to aggregate (Yang et al., 2003).
The accumulation of Aβ in the brain leads to damage of neurons which in turn triggers
inflammatory responses as the brain attempts to repair itself (Harman, 2006).
The concept of Aβ-derived soluble toxic oligomers has been proposed to account
for the neurotoxicity of the amyloid-β peptide. These intermediate forms lie between free,
soluble Aβ monomers and insoluble amyloid fibrils (Zhang-Neus et al., 2006). Soluble
Aβ oligomers are organized into different structures ranging from dimers (Walsh et al.,
2002) to dodecamers (Lesne et al., 2006) and include; trimers (Walsh et al., 2002; Glabe,
2006), tetramers (Walsh et al., 2002; Glabe, 2006), pentamers and decamers (Ahmed et
al., 2010), and Aβ-derived diffusible ligands (ADDLs) (Hepler et al., 2006, Lambert et
al., 1998). Additionally, the role of different cleavage variants, Aβ1–40 and Aβ1–42, has
been under investigation for some time. They are the two dominant Aβ peptides produced
by β-secretase and γ-secretase. In vitro, Aβ1–40 tends to be more stable in isolation and
remains in the monomer stage longer before it aggregates to form fibrils. Aβ1–42 tends to
remain in a mix of monomer, trimer, and tetramer form until it aggregates into fibrils
(Sengupta et al., 2016).
Toxic, soluble Aβ species in different forms have been isolated from transgenic
mouse brains and the human brain in vitro under various experimental conditions (Karran
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et al., 2011; Mattson, 2000; Oddo et al., 2003). Dodecamers appear to be diffuse
throughout the tissue and exert toxic effects in cultures. Aβ oligomers contain mainly
replicates of Aβ trimers and were identified in the brains of Tg2576 mice (Lesne et al.,
2006). This soluble aggregate of Aβ appears to impair memory function in these animals,
irrespective of neuronal loss and leads to synaptic dysfunction in humans (Lesne et al.,
2006). Consistent with its toxic effects, these Aβ oligomers were also found to correlate
with markers of synaptic dysfunction and levels of hyperphosphorylated tau (Sengupta et
al., 2016). This suggests that toxicity is dependent on the size, aggregation state, and
diffusion of Aβ oligomers.

Figure 3. Processing of Amyloid Precursor Protein. In Panel A, α-secretase cleaves the
amyloid precursor protein (APP) initiating the nonamyloidogenic processing. sAPPα and
a carboxy-terminal fragment, C83 is then produced and C83 is further digested by γ
secretase, liberating the amyloid intracellular domain (AICD). β-secretase beta-site
amyloid precursor protein cleaving enzyme 1 (BACE-1), cleaves APP releasing sAPPβ
and C99, initiating the amyloidogenic processing. Further C99 is digested by γ secretase
releasing Aβ. Reproduced with permission from (Querfurth and LaFerla, 2006),
Copyright Massachusetts Medical Society.
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Aβ Clearance. Aβ clearance from the brain occurs through enzymatic and nonenzymatic pathways. Non-enzymatic pathways include 1) the bulk flow of the interstitial
fluid (ISF) into the CSF by ISF drainage pathway through perivascular basement
membranes, (Cserr, 1983; Hladky and Barrand, 2014; Bedussi et al., 2015) 2) the uptake
by microglial or astrocytic phagocytosis (Jones et al., 2013; Fu et al., 2014), and 3) the
transport across the blood brain barrier mediated by clearance receptors such as lowdensity lipoprotein receptor-related protein 1 (LRP1) (Jones and Shusta, 2007; Storck et
al., 2016; Fiala et al., 1998), very low-density lipoprotein receptor (VLDLR) (Holtzman
et al., 2012; Deane et al., 2009) and P-glycoprotein localized predominantly on the
abluminal side of the cerebral endothelium (Terasaki and Ohtsuki, 2005; Cornford and
Hyman, 2005).
Enzymatic clearance pathways include the Aβ-degrading enzymes neprilysin
(Yoon and Jo, 2012; Baranello et al., 2015; Hafez et al., 2011), insulin-degrading enzyme
(IDE) (Duckworth et al., 1998; Bates et al., 2009), and matrix metalloproteinase-9
(MMP9) (Miners et al., 2008; Yoon and Jo, 2012).
Aβ is trafficked via the interstitial fluid (ISF) into the CSF via bulk flow;
however, this has been shown to be a minor route for Aβ clearance in mice, as it only
accounts for approximately 10% of Aβ clearance (Fagan et al., 2009). Microglia, the
brain's local macrophages, play an essential role in Aβ clearance through their ability to
take up and degrade soluble and fibrillar forms of Aβ (Rogers et al., 2002; Lee and
Landreth, 2010; Jiang et al., 2008). Both microglia and astrocytes secrete proteinases,
including IDE, that mediate the degradation of Aβ peptides in the extracellular
environment (Butovsky et al., 2007). Microglial cells have neuroprotective actions by
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producing neurotrophic factors and by eliminating Aβ from the brain by phagocytosis
before formation of senile plaques (Kurochkin and Groto, 1994; Simard and Rivest,
2006; Harry and Kraft, 2008).
The other route for Aβ clearance is direct trafficking out of the brain via the
blood–brain barrier (BBB) into peripheral circulation (Shaw et al., 2009). Astrocytes, a
component of BBB plays a role in plaque maintenance and Aβ clearance (Lee and
Landreth, 2010; Kraft et al., 2013). Animal experiments demonstrated that astrocytes
internalize Aβ by receptors such as LRP1, which has a function to transcytose ligands
across the BBB. LRP1 also has the capability to uptake Aβ bound to apolipoprotein
(Zhao et al., 2009). Aβ1-40 is cleared rapidly across the BBB via LRP1 while Aβ1-42 is
removed across the BBB at a slower rate (Thal, 2012; Deane et al., 2009; Storck et al.,
2016).
The brain contains vigorous essential Aβ clearance mechanisms (Tanzi et al.,
2004). Aβ peptides are proteolytically degraded within the brain principally by neprilysin
(Iwata et al., 2004; Baranello et al., 2015; Hafez et al., 2011) and IDE (Kurochkin and
Goto, 1994; Duckworth et al., 1998; Bates et al., 2009). Administration of inhibitors of
these proteinases into the brain results in substantial elevation of Aβ levels in the brain
and stimulation of plaque deposition (Dolev et al., 2004). On the other hand,
overexpression of neprilysin or IDE lowered brain Aβ levels and reduced plaque
formation (Lehman et al., 2003). It has been argued that the principal approach of Aβ42
clearance from the brain is through its proteolytic degradation because this peptide is not
efficiently transferred through the vasculature (Jiang et al., 2008).
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Other Hypotheses of AD
While the amyloid cascade hypothesis is currently the most widely accepted
hypothesis of AD, other hypotheses have been proposed. These hypotheses tend to
incorporate the development of plaques that are found between the dying cells in the
brain; from the build-up of a protein, Aβ (Harman, 2006; Fulda et al., 2010), neuritic
plaques (NPs) (Serrano-Pozo et al., 2011; Li et al., 2016), tau protein dysfunction
(Mondragon-Rodriguez et al., 2014), and intracellular neurofibrillary tangles (NFTs) (De
Strooper, 2010).
Studies on the correlation of NFTs and NPs to cognitive deterioration in AD have
yielded differing results (Nelson et al., 2007). For this reason, NFTs and NPs may
contribute only slightly to dementia, or NFTs and NPs are less relevant to cognitive
decline in older patients with AD than other pathologic processes (De Strooper, 2010;
Nelson et al., 2007). A study quantitatively assessing the numbers of intracellular and
extracellular NFTs in AD brains and of controls, found that in some cases, NFTs were
not removed from the brain throughout the disease process (Mattson, 2000). This finding
provides evidence that the protein constituent of NFT is resistant to proteolytic removal
due to extensive cross-links. Additionally, correlation between the number of NFTs and
neuronal loss indicates there are at least two distinct mechanisms responsible for neuronal
death in AD that is related to the presence of neurofibrillary pathology (Yang et al.,
2003).
Another proposed pathological component of AD, paired helical filaments of tau
are formed first in the intracellular space of the neuron, and coalesce to form NFTs in the
soma and axonal processes. At the same time or a little later, precursor proteins (either in
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the dimeric or higher aggregated forms) are deposited in the extracellular space
associated with the pre-synaptic axonal processes. These deposited proteins form the
amyloid fibrils which may either crystallize within the center of a plaque, or the fibrils or
their precursor subunits may migrate and accumulate around and within the walls of
small blood vessels (De Strooper, 2010).
Aβ aggregation and deposition triggers a process that leads to neuronal loss via
the formation of paired helical filaments of tau (Saido et al., 1995,1996; Fagan et al.,
2009). Nonetheless, it remains to be clarified how deposited Aβ triggers or accelerates
tau pathology and how tau pathology ultimately leads to neuronal loss (Fiala et al., 2007).
However, a recent study demonstrated that the formation of intracellular amyloid-like
fibrils resulted in the seizing of key intracellular proteins, which then led to the imbalance
of essential cellular processes (Mucke and Selkoe, 2012). It is possible that intracellular
tau aggregates act in a similar fashion (Glabe, 2006). Tau pathology follows a regular
neurological path that correlates with the observed sequence of cognitive defects. Tau
pathology also correlates with neuronal loss and cerebral atrophy, which in turn
correlates with dementia. In addition, preclinical evidence suggests that in the absence of
plaques, tau pathology can spread throughout the brain (Hardy, 2005).
In summary, Aβ aggregation and deposition is a very early event that can trigger
tau pathology and will do so in many individuals, but the deposition of Aβ does not
correlate with the presence of neurofibrillary tangles, cell loss or dementia. Given the
current knowledge discussed above, and recognizing that there are considerable gaps in
our understanding of AD pathology, one hypothesis that accommodates most of the
known data is that Aβ aggregation and deposition triggers a process that leads to neuronal
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loss. Nonetheless, it remains to be clarified how deposited Aβ ultimately leads to
neuronal loss.

Genetic Aspects of AD
Early studies in familial AD (FAD) identified a locus on the long arm of
chromosome 21, the region known to be duplicated in Down's syndrome, that encodes for
APP. Subsequently, seven different mutations in the same gene have been found, all of
which increase the production of Aβ 1–43 leading to fibrillar aggregation toxic to
neurons (Shen and Kelleher, 2007).
Autosomal dominant mutations that cause early onset familial AD (eFAD) occur
in three genes: presenilin 1 (PSEN1), presenilin 2 (PSEN2), and APP (Mattson, 2000).
PSEN1 and PSEN2, are homologous proteins that can form the catalytic active site of
gamma-secretase. Also apolipoprotein E (APOE) gene represents the major genetic risk
factor for AD (Pastor et al., 2003). Humans contain three common APOE alleles:
APOE2, APOE3 and APOE4. The APOE4 allele is responsible for the age of disease
onset, APOE3 is neutral, and APOE2 may be protective (Dal Forno et al., 2002; Karran et
al., 2011). Compared to individuals lacking APOE4 alleles, the risk for people who
possessed one APOE4 allele were at a 2-3-fold increase while individuals with two
APOE4 alleles were at a 12-fold increase in AD onset (Kim et al., 2009). A series of
experiments in some APP transgenic mice that had the human APOE genes indicate that
these associated proteins facilitate the clearance of amyloid-β, with APOE3 and APOE4
being increasingly less effective at clearing Aβ (Allan and Ebmeier, 2011; Karran et al.,
2011).

12

Other AD risk factor genes are being discovered via genome-wide association
(GWA) studies. Of interest, the genes that cause the autosomal dominant form of the
disease have not been detected as risk factors in the GWA studies that have been
conducted so far (Van Broeckhoven and Kumar-Singh, 2006). The most likely
explanation for this is that the common genetic variation around these three genes is
simply not sufficient to alter their expression in a way that increases the risk of AD
(Jones et al., 2010).
The amyloid cascade hypothesis appears to explain and incorporate several key
points that are relevant to the disease process, including the pathology, the phenotypes
mediated by the genes that cause autosomal dominant disease, and the genetic risk caused
by the APOE gene (Morris et al., 2010). However, this hypothesis does not consider the
interaction of Aβ with tau. This was clarified, to some degree, by the discovery that
mutations in the tau gene could cause dementia in the frontal lobe. Thus, tau pathology
itself can cause neuronal loss. This observation places tau pathology downstream of Aβ
pathology (Dal Forno et al., 2002).
For the FAD-linked APP gene mutations, there are potential effects that predispose individuals to early onset AD. If the amount of Aβ42 is increased sufficiently,
then early onset AD can result. For the amyloid-β C-terminal APP mutations, the increase
in the Aβ42/Aβ40 ratio is sufficient to cause early onset AD (Querfurth and LaFerla,
2006). For the presenilin mutations, the increase in the ratio of longer Aβ42 or Aβ43
versus shorter Aβ40 or Aβ38 species, even in the framework of an overall reduction in
amyloid-β production, is sufficient to cause early onset AD (Winkler et al., 2012). A
recent study confirmed that Aβ43 is at least as pathogenic as Aβ42, and studies in
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patients demonstrated that the ratio of Aβ peptides in the CSF of carriers of the presenilin
1 mutation was substantially different from control patients and patients with sporadic
AD (SAD) (Lippa et al., 1996).
Increases in the Aβ42/Aβ40 ratio or increases in the levels of Aβ42 or Aβ43 in the
brain will cause individuals to develop AD (Bernstein et al., 2009; Lee and Han, 2013).
However, the duration of the disease appears to be unchanged by genetic factors. This
implies that changes in the amount of Aβ or Aβ ratios are not important modifiers of the
disease process (Pike et al., 1993; Glabe, 2006). The reduction in Aβ42 levels in the CSF
is an early event in the disease process (Fagan et al., 2006, 2009) but there are very few
studies demonstrating that once Aβ deposition has occurred, the amount of deposition can
be correlated with neuronal loss, paired helical filaments of tau or dementia.

Therapeutic Strategies
It is always preferable to treat any disease as early as possible. If the trigger event
is the onset of Aβ deposition, then testing the amyloid cascade hypothesis would require
a clinical trial in cohorts with normal scans of people who are at risk of developing AD
(De Meyer et al., 2010). This represents a huge clinical challenge, including the selection
of the clinical trial population and ethical considerations (Karran et al., 2011).
An effective treatment for SAD depends on the interpretation of the disease
pathways. Prospective studies show that cognitive leisure activity and training can lower
the risk of dementia (Verghese et al., 2003). Findings from these studies provide support
for the concept of building a cognitive backup. Epidemiological studies suggest that
simple lifestyle changes may be adequate to slow the onset and progression of AD (Pope,
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2003; Beckett et al., 2015; Scarmeas et al., 2009; Buchman et al., 2012; Scarmeas et al.,
2011; Larson et al., 2006; Lindsay et al., 2002; Podewils et al., 2005; Abbott et al., 2004;
Yoshitake et al., 1995; Ravaglia et al., 2008).
There are several strategies that are being developed to identify risk factors for the
development of AD. Plasma cortisol levels, a widely used physiological marker of the
stress state, have been correlated with the progression of AD (Dong and Csernansky,
2010; Csernansky et al., 2006). There have been reports of chronic isolation stress which
leads to accelerated plaque development in certain mouse models of AD (Dong et al.,
2008; Rothman and Mattson, 2010; Hebda-Bauer et al., 2013; Cordner and Tamashiro,
2016). Exercise training reduces oxidative stress and improves neuron regulation which
counteracts damages from stress and age related neuronal degeneration (Kiraly and
Kiraly, 2005; Cho and Roh, 2016). Friedland et al. (2001) validated that patients with AD
were less active, both intellectually and physically, in midlife and that sedentariness was
associated with a 150% increased risk of developing AD (Friedland et al., 2001).
Similarly, Laurin et al. (2001), also demonstrated that physical activity was protective
against the development of cognitive impairment (Laurin et al., 2001). Exercise training
may be a major protective factor but without clinical guidelines, its prescription and
success with treatment adherence remain elusive (Kiraly and Kiraly, 2005). The
remainder of this review will focus on physical activity and exercise training as a
preventative measure against the development of chronic disease in general and AD
specifically.
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Physical Activity and Disease
Physical activity has been shown to elicit positive effects in the prevention and
delay of chronic diseases such as cardiovascular disease, depression, diabetes, and breast
cancer (Morris et al., 1973; Dunn and Dishman, 1991; Knowler et al., 2002; Friedenreich
and Cust, 2008). The most universally studied of the above-mentioned diseases is
cardiovascular disease, and the role that physical activity plays in it has been welldefined. Extensive study into neurological diseases has provided evidence indicating that
the risk factors for cardiovascular disease overlaps with AD (Kesaniemi et al., 2001).
Several epidemiological studies have shown that the switch from a sedentary to a
physically active lifestyle reduces AD risk in humans (Fletcher et al., 1996; McGough et
al., 2011; Vreugdenhil et al., 2012).
Physical Activity and Exercise Training. According to Casperson et al. (1985),
physical activity could be divided into categories that are mutually exclusive of each
other. Physical activity can be divided into light, moderate, or moderate intensity; those
that are willful or compulsory; or those that are weekday or weekend activities. These are
adequate ways of subdividing physical activity and the only condition is that the
subdivisions be mutually exclusive and that they sum to the total caloric expenditure due
to physical activity which may relate to a specific aspect of health (Casperson et al.,
1985). For example, physical activity of high intensity in a structured, planned, and
repetitive manner could result in an exercise training effect leading to an improved
physical fitness state, and better health. Existing work in the field of exercise physiology
suggests that normal daily physical activity (light physical activity) alone does not reduce
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the risk of diseases but an exercise training strategy typically results in a state of
increased physical fitness (Haskell, 1994).
Physical Activity in AD. It is becoming apparent that several risk factors for
cardiovascular disease are also risk factors for neurodegenerative diseases including AD.
Lower motivation of AD patients to exercise training regimens could be an obstacle for
clinical studies, although this can be overcome, at least in part, by experimental studies
(Selkoe and Schenk, 2003). Wilson and his group reported that physical activity for only
several hours a week was associated with the risk of development of AD in small
populations (Wilson et al., 2002). Epidemiological studies show that midlife physical
activity was associated with delayed AD onset (Fratiglioni et al., 2004; Coltman and
Berchtold, 2002; Andel et al., 2008). Physical activity improved cognition in adults with
AD and those with cognitive impairment and dementia (Heyn, 2004; Smith et al., 2014;
Etneir et al., 2006; Colcombe and Kramer, 2003; Brown et al., 2013). Also, intervention
studies suggest that physical activity may have an impact in reducing AD risk although
volume and intensity of exercise training have not been defined.
Physical Activity and AD Transgenic Mouse Models
Because human epidemiology investigations are limited in their ability to study
mechanisms related to AD, investigators have developed transgenic mouse models of the
disease to use in this area of research. These studies, summarized in Table 1, have
investigated physiological mechanisms underlying the effects of physical activity and
exercise training on delaying the onset and slowing the progression of the disease
process.
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Table 1: Physical activity paradigms used in AD transgenic mouse models
Study
Adlard et al
2005
Wolf et al
2006
Cracchiolo et
al 2007
Nichol et al
2007
Parachikova
et al 2008
Richter et al
2008
Um et al
2008
Cho et al
2010
Cho et al
2015
Um et al
2011
Kang et al
2013
GimenezLlort et al
2010
Ke et al
2011
Liu et al
2011
Liu et al
2013
Garcia-Mesa
et al 2011
Garcia-Mesa
et al 2012
Garcia_Mesa
et al 2016
Xiong et al
2015
Zhao et al
2015
Yuede et al
2009

Mode
Wheel
Running
Wheel
Running
Wheel
Running
Wheel
Running
Wheel
Running
Wheel
Running
Treadmill
Running
Treadmill
Running
Treadmill
Running
Treadmill
Running
Treadmill
Running
Treadmill
Running

Intensity
3-7-6.0
m/min
Not
reported
Not
reported
2.4 m/min

Duration
12 hr/day

Frequency
7 days/week

Length
5 months

12 hr/day

7 days/week

8.5 months

12 hr/day

7 days/week

3 months

12 hr/day

7 days/week

2 months

Not
reported
2.0 m/min

12 hr/day

7 days/week

3 weeks

12 hr/day

7 days/week

10 weeks

13.2 m/min

60 min/day

5 days/week

16 weeks

13.2 m/min

60 min/day

5 days/week

16 weeks

10 m/min

60 min/day

5 days/week

5 weeks

12.0 m/min

60 min/day

5 days/week

3 months

10 m/min

60 min/day

5 days/week

5 weeks

4.2 m/min

30 min/day

5 days/week

5 weeks

Treadmill
Running
Treadmill
Running
Treadmill
Running
Wheel
Running
Wheel
Running
Wheel
Running
Treadmill
Running
Treadmill
Running
Wheel
Running

10 m/min

60 min/day

5 days/week

5 weeks

11 m/min

30 min/day

5 days/week

5 months

11 m/min

30 min/day

5 days/week

5 months

Not
reported
4.0 m/min

12 hr/day

7 days/week

6 months

12 hr/day

7 days/week

6 months

3.3 m/min

12 hr/day

7 days/week

3 months

15 m/min

300 m/day

6 days/week

5 months

11 m/min

30 min/day

5 days/week

5 months

10.9 m/min

60 min/day

5 days/week

4 months
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Yuede et al
2009
Moore et al
2016

Treadmill
Running
Treadmill
Running

10.9 m/min

60 min/day

5 days/week

4 months

15 m/min
and
32 m/min,
10% grade

60 min/day

5 days/week

3 months

Overview of Physical Activity in AD Transgenic Mouse Models. Physical
activity as a method of decreasing cardiovascular disease risk has been studied using
animal models for more than 50 years. This body of work is highly sophisticated in its
construction of physical activity paradigms which assess the intensity, volume, and mode
of physical activity and exercise training and the relationship of those variables to
reducing cardiovascular disease risk. In contrast, physical activity has been investigated
as an intervention against AD pathology in transgenic mouse models for only slightly
over a decade beginning with the study of Adlard et. al. published in 2005. Except for
Moore et al. (2016) these studies have not quantified physical activity in a manner that
would allow the assessment of the effect of physical activity level on reducing risk of
developing AD pathology.
Physical activity and exercise training studies using AD transgenic mouse models
have utilized running wheels or motor driven treadmills in the administration of these
treatments. As with all treatment programs, there are advantages and disadvantages to
each mode of physical activity. Running wheels are advantageous in that they allow for
voluntary activity for the animals, however, their disadvantage is that they do not allow
for precise regulation of the intensity nor the volume of the activity in which the animals
engage. With running wheels, it is not difficult to quantify the distance a mouse covers
during a period of time (i.e., a 12 or 24 hour period), but it is not possible to know
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anything about the manner in which the mouse covered that distance. For example, some
mice will run in the wheel at a constant, slow speed, whereas, others will run in bursts of
high speed followed by periods of no activity.
Another problem with wheel running is that there is a wide variation in running
distance among animals within a study, making data interpretation difficult because
health benefits of physical activity and exercise training are related to the amount of
physical activity performed (Bherer et al., 2013; Noble et al., 1999). Treadmill running,
on the other hand, allows for precise regulation of exercise training, but has been
criticized as being a stressful intervention (Yanagita, et al., 2007). This could be
detrimental in the study of AD as it has been demonstrated that stress accelerates plaque
development and cognitive decline in AD transgenic mice (Dong et al., 2004; Yuede et
al., 2009). The work of Yuede et al. (2009), comparing voluntary wheel running and
treadmill running to sedentary controls does not fully support this concern however.
Plaque counts were found to be lower in Tg2576 mice subjected to wheel running than
those subjected to treadmill running. However, mice running on treadmills had lower
plaque counts than sedentary mice, indicating treadmill running was an improvement
over a sedentary lifestyle. Wheel running mice did have lower plaque count than
treadmill running mice. In addition, however, hippocampal volume was similar between
wheel running and treadmill running mice and both were greater than sedentary mice.
It is important in studies of physical activity and exercise training that some
measure of improved physical fitness is assessed to demonstrate a training effect. This
generally takes the form of an increase in maximum oxygen consumption of the animal
or an increase in one of the mitochondrial oxidative enzymes in a working skeletal
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muscle, the classic being citrate synthase (CS). To date only Moore et al. (2016) have
done this in a study using an AD transgenic mouse model. When comparing wheel
running to treadmill running, it has been demonstrated in rats that treadmill running
results in increased soleus muscle CS activity (Bedford et al., 1979; Hilty et al., 1989),
whereas, voluntary wheel running does not demonstrate this even when animals are
divided into high and low running groups (Rhodes et al., 2005; Yancey and Overton,
1993; Noble and Farrell, 1994). Therefore, future study of physical activity and exercise
training effects on delaying the onset and slowing the progression of the disease process
in AD transgenic mouse models should utilize treadmill running to precisely regulate
exercise intensities and volume.
Effects of Physical Activity on Soluble Aβ and Plaque. The Aβ peptide is
normally present in the interstitial fluid of the brain in soluble form throughout life
(Cirrito et al., 2003). In AD pathology, Aβ aggregates into toxic soluble oligomers and
eventually insoluble plaque in a concentration dependent manner (Bero et al., 2011).
Therefore, strategies, including physical activity, aimed at reducing soluble Aβ in the
brain prior to disease onset have been investigated as a method of delaying the onset and
slowing the progression of AD pathology.
AD transgenic mouse studies investigating the effects of physical activity on
amyloid pathology have been equivocal. Physical activity has been shown to either
decrease (Adlard et al., 2005; Lararov et al., 2005; Um et al., 2008; Yuede et al., 2009;
Liu et al., 2013; Tapia-Rojas et al., 2016) or not change (Cracchiolo et al., 2007) brain
amyloid plaque levels. Likewise, brain soluble Aβ levels have been found to decrease
(Adlard et al., 2005; Um et al., 2008) or not change (Yuede et al., 2009) with physical
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activity. A likely explanation for the equivocation is the differences in the physical
activity paradigms among the studies. As stated above, some used wheel running others
treadmill running. It is entirely possible that the variation in intensity of physical activity
in these studies accounted for the different results.
To address this likelihood, Moore et al. (2016) conducted a study to more
thoroughly investigate the effect of physical activity dose on soluble Aβ levels in the
hippocampus and cortex of Tg2576 mice. Three groups were utilized, a sedentary group,
a moderate intensity treadmill running group (15 m/min on a level treadmill), and a high
intensity group (32 m/min, 10% treadmill grade). All animals in the treatment groups ran
for 60 minutes per day, five days per week, for 12 weeks. The sedentary animals were
placed on a stationary treadmill for an equal amount of time each day. The results
demonstrated a clear dose-response of Aβ40 and Aβ42 to exercise training intensity.
Additionally, the study demonstrated that the reduction of Aβ40 and Aβ42 was due to
increased clearance as measured by a dose dependent upregulation of the Aβ degrading
enzymes neprilysin, IDE, and MMP9, the blood brain barrier transport protein, LRP1,
and the molecular chaperone, HSP70. The moderate intensity treadmill running protocol
in this study was more intense than the physical activity protocols in most of the previous
studies summarized in Table 1. This indicates a likely minimum physical activity
intensity threshold below which the effect of the physical activity is not realized and
suggests that investigators in the future much more precisely assess physical activity
levels in the study of physical activity effects on AD pathology.
It is also likely that the differences among studies investigating physical activity
on amyloid plaque in AD transgenic mice can be attributed to differences in physical
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activity intensity as described above for soluble Aβ. At this point no study has been
made of the effect of physical activity intensity on amyloid plaque. It will be the purpose
of the study undertaken here to do so.
Physical Activity on Tau. Studies of the effect of physical activity on Tau and
NFPs have been limited compared with those investigating Aβ. Belarbi et al. (2011)
looked at the effects of 9 months of voluntary physical activity in THY-Tau22 mice and
there was prevention of memory alterations, cholinergic defects, inflammatory and
metabolism related modifications. Treadmill running has been shown to ameliorate the
accumulation of phosphorylated tau in AD mouse models (Stranahan et al., 2012). In a
long-term exercise training study, general locomotor and exploratory activity were
exhibited in P301S tau transgenic mice along with reductions in full-length and
hyperphosphorylated tau (Ohia-Nwoko et al., 2014).
Physical Activity and other factors. Symptoms such as weight loss, fatigue,
decreased food intake, and weakness have been demonstrated in AD patients who are
inactive. Physical activity in the form of a structured exercise paradigm may be beneficial
to AD patients by improving learning, plasticity, angiogenic factors, cerebrovascular
function and lower production of Aβ42 (Walsh et al., 2002).
High levels of Aβ42 deposition mediates apoptosis of neuronal cells or apoptosis
itself. But exercise training improves neuronal function by modulating neurogenesis,
synaptic plasticity, learning, and memory (Kuperstein et al., 2010). However, the
mechanisms by which apoptosis is modulated by exercise training in AD remains
uninvestigated. De Strooper (2011) evaluated exercise training to determine whether it
could prevent or improve cell death in the brains of transgenic (Tg) mice, as found in AD
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patients. The study demonstrated that caspases, Bax protein levels, and cytochrome c
were significantly reduced in Tg mice brains that were exercised trained compared to
sedentary control.
Pro-apoptotic protein (cytochrome c and Bax) reduction post exercise training in
APP Tg mice may be mechanistically related to lower Aβ42 levels which may be
mediated through apoptotic pathway inhibition (Anderson et al., 1996). Importantly in
this study, the Tg mice brains had elevated levels of Bcl-2, an apoptotic protein,
compared to sedentary control. This observation is critical because a previous study
demonstrated that exercise training can result in neuronal resistance against oxidative and
apoptotic damages mediated through reduction in Aβ-induced apoptosis (Molteni et al.,
2002). Therefore, these results suggest that apoptosis of neurons responsible for AD
pathogenesis can be modulated by exercise training which increases the clearance of Aβ.
Neurotrophic factors such as NGF, BDNF and CREB, which are known to link
adult hippocampal neurogenesis and hippocampal function were decreased in AD and are
clinically associated with Aβ42 depositions in the brain of AD animals and patients.
Therefore, establishing the rationale for using treadmill exercise training as nonpharmacological approach for elevating neurotrophic factors has received the greatest
attention from AD investigators (Lesne et al., 2006).
Chen and Russo-Neustadt (2009) demonstrated that hippocampal NGF, BDNF
and CREB levels were down-regulated in Tg mice compared with non-Tg mice, but they
were up-regulated after treadmill exercise training, indicating that treadmill exercise
training increased levels of hippocampal NGF, BDNF and its downstream effectors
CREB, which are important for cognitive function in Tg-NSE/PS2m mice. The
24

underlying molecular mechanisms could indicate that treadmill exercise training has the
potential to enhance cognitive function in Tg-NSE/PS2m mice, possibly through an
increased level of NGF, BDNF and CREB, which are important for neurogenesis in the
hippocampus. This result indicates that treadmill exercise training has a better ability to
induce antioxidant enzymes to cope with the oxidative stress formed in the brain of Tg
mice with AD.
Heat shock proteins (HSPs) are ubiquitously expressed intracellular proteins that
protect proteins and DNA from stress-induced damage. HSP-70 has been reported to
inhibit the self-assembly of poly-glutamine proteins into amyloid-like fibrils. However,
till recently, it was not known whether HSP-70 increases within the brains of ADtransgenic mice during exercise training (Hardy, 2005). Jones et al. (2010) showed that
hippocampal HSP-70 level was down-regulated in Tg mice compared with non-Tg mice,
and that the level of this protein in Tg mice was up-regulated after treadmill exercise
training (Jones et al., 2010). Moore et al. (2016) demonstrated that HSP-70 was elevated
by treadmill exercise training in a dose-dependent manner. These findings indicate that
treadmill exercise training contributes to a neuroprotective effect on the brain of Tg mice
with AD, suggesting that increased level of HSP-70 protein following treadmill exercise
training may benefit the brain, making it more resistant to stress induced cell damage
(Mosser et al., 1997; Broer et al., 2011).
Exercise training is suggested to reduce Aβ accumulation in cortical areas of AD
transgenic mouse by increasing proteolytic degradation by proteasome. The exact
molecular mechanisms underlying these favorable effects of exercise training in brain are
not well known, but the MAPK, PI3K, and PI/Akt signaling pathways and the
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transcription factor CREB have been involved at the molecular level (De Strooper, 2010).
Exercise training also can change the function of glutamatergic systems, increasing
NMDA receptor in the hippocampus, which are crucial in learning and memory
processes. The health and psychological benefits elicited by regular physical activity in
older adults contribute to healthy aging. Therefore, physical exercise training is a
potential intervention to preserve or ameliorate cognitive function and behavior in AD
(Khachaturian et al., 2011).
Taken together, any or all of the above-mentioned proteins are potential triggers
for the neuronal cell death and survival. Therefore, studies investigating death and
survival of neuronal cells exposed to AD would be a step in the search for therapy
leading to recovery from AD and explanation of molecular mechanism responsible for
the effect of therapeutic interventions such as exercise training to repress neuronal cell
death (Yuan et al., 2003; Kang et al., 2013).
In summary, several studies in transgenic mouse models of AD suggest exercise
training reduces soluble and insoluble Aβ levels in the brain. Epidemiological studies
suggest that physical activity exerts beneficial effects on humans. But as reviewed
extensively here, the lack of a specific exercise paradigm raises the question of
quantifying exercise training in a controlled experimental setting to address dosedependent beneficial effects. This study is the second part of an investigation into the
dose response of exercise training on AD pathology. In the first part, Moore et al. (2016)
demonstrated that three months of exercise training in young Tg25756 mice reduced
soluble Aβ40 and Aβ42 and upregulated multiple Aβ clearance proteins in an exercise
training dose dependent manner. This study extended the treadmill running employed by
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Moore et al. (2016) to 12 months in the same mouse model and investigated its effect on
amyloid plaque levels in the cortex and hippocampus and on cognitive function.
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MATERIALS AND METHODS
Animals
This study was approved on 17 September 2010 by the Institutional Animal Care
and Use Committee (IACUC), protocol number 10024. Tg2576 mice, from our in-house
colony, expressing human APP695 with double mutations K670N and M671N driven by
the hamster prion protein [147] were used for this study. Hemizygous male Tg2576 mice
maintained on C57B6/SJL background were crossed with wild type C57B6/SJL females.
Only male Tg2576 offspring were used in this study. Animals were housed individually
in Optimize ventilated cages and provided food and water ad libitum. Tail snips were
acquired at the time of weaning, 3 weeks of age, to confirm transgene expression.
Genotyping was performed using a QIAGEN QIAamp Mini Kit (cat. no. 51304,
Valencia, CA) to purify DNA, followed by RT-PCR analysis.

Experimental Design
Animals in high intensity (HI) and low intensity (LOW) groups were placed on a
motor driven treadmill (Columbus Instruments, Columbus, OH) with an electric grid for
motivation for 1 hour each day, 5 days per week, for 12 months. LOW animals ran at a
speed of 15 m/min, 0% grade. HI animals ran at a speed of 32 m/min, 10% grade, as we
have previously observed that most animals are able to run at this speed for one hour
daily (Moore et al., 2016). Sedentary (SED) animals were removed each day from their
home cage and placed on an immobile treadmill to keep handling and environmental
stimuli consistent among groups.
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Table 2: Summary of experimental design.
HI
3 months

LOW
3 months

SED
3 months

12 months

12 months

N/A

Speed

32 m/min,10%
grade

15 m/min, 0%
grade

N/A

Age at time of
behavioral analysis

14 months

14 months

14 months

Age at end of
Exercise training

15 months

15 months

15 months

Age at beginning of
exercise training
Run time

Body Weights and Food Intake
Body weights of animals were monitored once at the end of every month during
the 12-month exercise training strategy. Baseline weights were recorded prior to the
training strategy. At the end-point, food consumption was monitored over 24 hrs prior to
sacrifice. All animals were individually housed so 30 grams of food was weighed and
provided to their home cages. 24 hrs later, food was weighed again and subtracted from
the previous weight.
Tissue Preparation
Animals were sacrificed at the end of month 12 of treatment by isoflurane. Brains
were promptly removed and immersed in 4% paraformaldehyde for 24 hrs then
transferred to a 30% sucrose solution to store for later histological analysis. The soleus
muscle was collected from each hind limbs and snap frozen on dry ice, and then stored at
-80 °C for citrate synthase analysis.
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Citrate Synthase Analysis
Following sonication in CellLytic MT buffer, soleus muscle citrate synthase (CS)
activity was assessed (Sigma Aldrich Citrate Synthase Enzyme Activity Kit, Appendix
A-1). Absorbance was measured at 412 nm on a BioTek Epoch plate reader and values
for left and right soleus muscles of each animal were averaged. Total protein was
quantified (Thermo Scientific™ Pierce™ BCA™ Protein Assay).

Tissue Sectioning and Amyloid Plaque Staining
Brain hemispheres were mounted for sectioning using Tissue-Tek® Optimal
Cutting Temperature (O.C.T.) compound (Electron Microscopy Sciences, Hatfield, PA).
Using a cryostat (Microm HM550, ThermoFischer Scientific, Walldorf, Germany),
coronal sections 40 µm thick were taken at the level of the hippocampus (5.5 mm deep)
and every 8th section was saved for staining.
DAB Staining. Sections were fixed and stained using mHJ3.4B, a biotinylated
reporter antibody specific to N-terminus of Aβ. After incubation with streptavidin-HRP,
Aβ plaques were detected by DAB and viewed using light microscopy. Plaque area in the
cortex and hippocampus was determined using NIH Image J software. Images were
captured for plaque staining at 40X magnification (Appendix A-2).
Thioflavin S Staining. Plaque staining was also analyzed with Thioflavin S
staining. Slides were incubated in filtered 1% aqueous Thioflavin-S (Sigma) for 5 min,
dehydrated twice in 70% ethanol for 5 min, and washed twice in PBS for 2 min. Mosaic
images were captured for amyloid plaque staining at 10X magnification (Appendix A-2).
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Behavioral Analysis
Mice were subjected to behavioral analyses during the last two weeks of treatment
in the form of open field, Morris water maze (MWM) and novel object recognition
(NOR) testing to evaluate spatial and recognition memory. Behavioral analysis was
tracked in real time by an overhead camera and videos were analyzed using the ANYMaze software (Stoelting Co).
Open Field. Mice were placed in the center of a white box (l38.5xw30xh30 cm)
and allowed to move freely for 10 min. The distance traveled and average speed were
measured using the Any-Maze software (Appendix A-3).
Morris Water Maze. Morris Water Maze testing was conducted in a 150 cm
diameter pool divided into four equal quadrants with the “goal quadrant” containing a
submerged platform that the mice had to find. Mice had a 7 day acquisition period with
four 60 second trials per day. Two days of cued trials first took place in which a tennis
ball denoted platform location. Four trials per cued day occurred where the submerged
platform was cycled through each quadrant. Mice were started opposite to the goal
quadrant in each of these trials. Five days of place trials then followed the cued trials. For
each of these successive trials, black shaped cues were placed on the walls surrounding
the pool and mice were started in a different quadrant using a random start pattern. In
both the cued and place trials latency (time to find platform) was recorded with a
maximum of 60 seconds allowed. If the animal did not find the platform within 60
seconds it was led to the platform. All animals, whether or not they found the platform,
were allowed to remain on the platform for 30 seconds. A single probe trial was
evaluated after a one hour delay following the last place trial. The platform was removed
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for the probe trial and percentage of time spent in the goal quadrant was recorded. All
MWM trials were evaluated using ANY-maze video tracking system (Stoelting Co.,
Wood Dale, IL) (Appendix A-4).
Novel Object Recognition. Mice were first acclimated to the test area for 20
minutes, one day before testing. On test day, each mouse had a sample trial and a test
trial. During the sample trial, the mouse was exposed to two identical objects for 10
minutes before returning to the home cage. After a 50 minute delay, the mouse was put
back into the test area for the test trial with one of the objects from the sample trial and a
novel object and exposed to the objects for 10 minutes. Test areas were cleaned with 70%
ethanol after each trial. Sample and trial sessions were recorded using ANY-maze
software. The time the animal spent with each object was assessed using a manual
stopwatch. Active investigation was described as facing the object within close
proximity (2 cm) and/or touching the object with forepaws. The amount of time spent
investigating the objects was recorded and the time spent investigating the novel object as
compared to the familiar object was analyzed as a measure of recognition memory (Leger
et al., 2013) (Appendix A-5).
Statistical Analysis
Experimenters were blinded during data analyses. Repeated measures ANOVA
was used to determine whether there was significant effects of treatment between objects
in object recognition test with exercise treatment (SED, LOW, HI) as the betweensubjects factor and the two objects (top, bottom; familiar, novel) as the within-subjects
factor. Repeated measures ANOVA was also used to determine whether there was
significant effects of treatment status between places trial days in MWM with exercise
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treatment as the between-subjects factor and the five days of place trials as the withinsubjects factor. One-way ANOVAs were performed to evaluate treatment effects on total
investigation times in sample and test trials for object recognition and probe trails using
MWM. One-way ANOVA was also used to analyze treatment effects on anxiety levels
by total distance in the arena and time spent in the center zone in the open-field test.
For body weights and food consumption, One-way ANOVA was used to evaluate
treatment effects between groups. Citrate synthase levels and amyloid-beta plaque levels
were analyzed using One-way ANOVA between groups as well.
All analyses were performed using GraphPad Prism version 6 with statistical
significance set at p < 0.05. If ANOVA suggested significant effects of group, Tukey’s
post-hoc comparison was used to evaluate between group differences. All data are
presented as mean +/- SEM.
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RESULTS
Body Weight and Food Intake
Sedentary (SED), High Intensity Exercise (HI), and Low Intensity Exercise
(LOW) groups all progressively increased in body weight throughout the course of the
study (Figure 4). Body weight did not differ among groups during the course of the study
(Appendix B-1).

Figure 4: Body weight increased similarily in mice in all three groups during the 12
month duration of the study. Mice were three months old when training began. (SED,
n=4; LOW, n=9; HI, n=5).

At the 14 month time point, food intake was assessed to check for a potential
exercise training effect on appetite. There were no differences in food intake among
groups over 24 hours (Figure 5, Appendix B-2).
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Figure 5: Food intake of mice, monitored over one 24-hour period, at the end of the
treatment program. Error bars represent SEM (SED, n=4; LOW, n=9; HI, n=5). Groups
are not statistically different from one another.

Citrate Synthase
Citrate synthase (CS) activity measurement is a standard test for assessing an
exercise training effect in mice. CS activity was significantly different among all three
groups (Figure 6). The HI group had a 110% increase in CS activity compared to the
LOW group and a 425% increase compared to the SED group. The LOW group had a
149% increase in CS activity compared to the SED. Thus, indicating a clear dose
response of the treadmill exercise paradigm in the groups (Appendix B-3).
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Figure 6: Citrate Synthase Activity. Values are expressed as activity of a gram of soleus
muscle/min. Error bars represent SEM (SED, n=4; LOW, n=9; HI, n=5). One-way
ANOVA and Tukey’s post hoc analysis: **significant at p < 0.0017, ***significant at p <
0.0001.
Amyloid Plaque
As Tg2576 mice are a model of AD, amyloid plaque levels were assessed after 12
months of exercise training via immunohistochemistry methods. Amyloid plaque load
was impacted by exercise training in both the cortex and hippocampus in a dose
dependent manner (Figure 7). The HI group had significantly lower percent area in the
cortex than the LOW (45.2%) and SED (58.5%) groups and the LOW group was
significantly lower than SED (24.4%). In the hippocampus the HI group plaque area was
significantly lower than the LOW (83.3%) and SED (88.6%) groups and the LOW group
was significantly lower than SED (31.4%). Representative images of plaque in the cortex
are shown in Figure 8 (Appendix B-4).
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Figure 7: A. Percent area of amyloid plaque in cortex. Values are expressed as
percentage of area in the cortex covered by amyloid plaques. Error bars represent SEM
(SED, n=6; LOW, n=6; HI, n=5). One-way ANOVA and Tukey’s post hoc analysis: *
significant at p <0.016, ** significant at p < 0.0054, *** significant at p < 0.0001. B.
Percent area of amyloid plaque in hippocampus. Values are expressed as percentage of
are in the hippocampus covered by amyloid beta plaques. Error bars represent SEM
(SED, n=6; LOW, n=6; HI, n=5). One-way ANOVA and Tukey’s post hoc analysis: **
significant at p < 0.0007 between the SED and LOW groups and ** significant at p <
0.0006 between the LOW and HI groups, *** significant at p < 0.0001

Figure 8: A. Representative images of ThioS staining of amyloid plaques at 10X
magnification. Orange arrows point towards the plaques in the cortex. Amyloid plaques
are lower in the HI group compared to the LOW and SED groups. Plaques are also lower
in the LOW group compared to the SED group. B. Representative images of DAB
staining of amyloid plaques in the cortex at 40X magnification. Amyloid plaques are
significantly lower in the HI group compared to the LOW and SED groups. LOW group
has lower plaques compared to SED group.
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Behavior
Open Field. A potential confounding factor for the beneficial effects of high
intensity treadmill exercise is whether the exercise routine modulates anxiety-like
behavior. In the open field test, there were no differences in total distance covered and
distance in middle grid between the HI, LOW, or SED groups (Figure 9, Appendix B-5).

Figure 9: Open Field Test – Locomotor Activity. Values are expressed as total distance
covered in the open field arena in area units. Error bars represent SEM (SED, n=4; LOW,
n=9; HI, n=5). One-way ANOVA. No significant differences between groups.
Morris Water Maze. Spatial memory was investigated using a Morris water
maze test. In the acquisition phase (Figure 10A), The HI group latency to the platform
was significantly lower on days 3, 4, and 5 compared to day 1. The LOW and SED
groups latency to the platform was significantly lower on day 4 compared to day 1 with
LOW being lower on day 5, but SED day 5 latency was not significantly different from
day 1. In the probe trial (Figure 10B and C), the HI group had a significantly faster time
to the platform location and spent a longer time in the target quadrant compared to the
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LOW and SED groups. The LOW group had a significantly faster latency to the platform
location than the SED group, however, the time spent in the target quadrant was not
different between the LOW and SED groups. Swimming speed was not different among
groups (Figure 10D, Appendices B-6 and B-7).

Figure 10: A. Morris water maze-acqusition phase. The HI group improved performance
compared to the LOW and SED groups. Error bars represent SEM (SED, n=5; LOW,
n=10; HI, n=6). B. Morris water maze-probe trial. The HI group had lower latency to
platform compared to the LOW and SED groups. Error bars represent SEM (SED, n=5;
LOW, n=10; HI, n=6). One-way ANOVA and Tukey’s post hoc analysis: ** significant
at p < 0.0019, *** significant at p < 0.0001. C. Morris water maze-probe trial. The HI
group spent more time in target quadrant compared to the LOW and SED groups. Error
bars represent SEM (SED, n=5; LOW, n=10; HI, n=6). One-way ANOVA and Tukey’s
post hoc analysis: *** significant at p < 0.0001). D. Morris water maze-probe trial.
Values expressed as swim speed in meters per second. Error bars represent SEM (Sed,
n=5; Mod, n=10; HI, n=6). One-way ANOVA. No significant differences between
sedentary, moderate, and high intensity groups.
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Novel Object Recognition. All groups investigated the similar objects equally at
approximately 50% in the sample trial (Figure 11A). In the test trial, the high intensity
mice investigated the novel object significantly more compared to the LOW and SED
groups which investigated the novel object and familiar object equally. Total object
investigation time did not differ among groups (Figure 11C, Appendices B-8 and B-9).

Figure 11: A. Object recognition test-sample trial. All groups spent the same amount of
time investigating the two similar objects within groups. Error bars represent SEM (SED,
n=9; LOW, n=10; HI, n=7). No significant differences existed among groups. B. HI
group spent more time investigating the novel object compared to the familiar object.
One-way ANOVA ad Tukey’s post-hoc analysis: *** significance at p < 0.0002. Error
bars represent SEM (SED, n=9; LOW, n=10; HI, n=7). No significance existed between
novel and familiar object recognition in LOW and SED groups. Object recognition testtesting phase. C. All groups had similar total investigation times. No significant
differences existed between groups. Error bars represent SEM (SED, n=9; LOW, n=10;
HI, n=7).
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DISCUSSION
Soluble Aβ is present in the interstitial fluid in the brain throughout life and
aggregates into amyloid plaques later in life in a concentration dependent manner
(Lomakin et al., 1997). Bero et al. (2011) published a definitive study on this topic
demonstrating, using microdialysis, a tight relationship between ISF Aβ early in life and
subsequent plaque deposition in aged mice in four different areas of the brains of Tg2576
mice. The findings of Bero et al. (2011) formed the conceptual basis for the two part
study performed in our lab of which the work reported here is the second part. In the first
part, Moore et al. (2016) found that soluble Aβ levels early in life were lower in the
cortex and hippocampus of Tg2576 mice that were exercise trained by treadmill running.
They further demonstrated that this effect was dose-dependent, in other words, the greater
the exercise training intensity the lower the soluble Aβ levels in both brain areas
assessed. This study utilized the exercise training paradigm of Moore et al. (2016), but
rather than stopping the training period at six months of age it was continued until 15
months of age to determine whether or not the amyloid plaque levels in the 12 month
exercise trained animals were reduced in a similar dose-dependent manner as the soluble
Aβ levels in the younger trained mice. This study also determined the effects of the
exercise training program on behavioral tests of anxiety, spatial memory, and recognition
memory.
Body Weight and Food Intake
High intensity treadmill exercise training, as employed in this study, could
potentially affect food intake and body weight of the mice. Studies throughout literature
overlook these factors during or post physical activity training, possibly because of lower
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running speeds or length of exercise regimen. Therefore, in the present study we
addressed this issue to identify potential negative peripheral effects of 12 months of
continuous treadmill exercise training.
It has been speculated that prolonged physical exercise could affect body weight
(Chaput et al., 2011). Therefore, we monitored body weight once each month over the
12-month exercise regimen. All groups progressively increased in weight, without any
significant differences among groups throughout the duration of the study. Various
studies report that wild-type and transgenic mice increase in weight as they age,
indicating that weight-increase over the lifetime of male mice is a natural effect (Inui,
2000; Ellacott et al., 2010; Gargiulo et al., 2014; List et al., 2014). The effect of exercise
training on body weight in mice is equivocal with some indicating that body weight does
not change in exercise trained mice and is lower than sedentary control mice (McMullan
et al., 2016; Toti et al., 2011), whereas, others (Evangelista et al., 2015; Kemi et al.,
2002) found no difference in body weight between sedentary and exercise trained mice.
The data from this study are similar to those of Evangelista et al. (2016) and Kemi et al.
(2002). The effect of exercise training on body weight in mice varies with different
studies for reasons that are not entirely clear. It may have something to do with the
intensity, duration and mode of the exercise training programs. A concern for us was that
the high intensity training regimen for a continuous 12-month duration may be stressful
to the animals, which may lead to weight loss. But the high intensity exercise trained
mice gradually increased in weight just as the low and sedentary groups, further
indicating that the mice adapted to the exercise intensity training regimen, which did not
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affect their ability to naturally gain weight as they aged. However, mechanisms related to
metabolism and weight gain/loss in exercise trained mice remains to be elucidated.
At the 14 month time point, food intake in all groups was assessed to determine
whether or not exercise training affected appetite. There were no differences in food
intake assessed 24 hours after the last day of training in any of the groups. These data
indicate that the exercise regimen employed in this study did not affect food intake
despite increased activity during exercise training between the high intensity, low
intensity, and sedentary groups. Future experiments monitoring food consumption more
regularly are needed to determine mechanisms relating to exercise treatment.
Assessment of Exercise Training
With the exception of Moore et al. (2016) from our laboratory no previous studies
investigating the role of physical activity in delaying the onset or slowing the progression
of Alzheimer’s pathology in AD transgenic mouse models attempted to assess the degree
of an exercise training effect. Like our pervious study we used citrate synthase activity in
this study as a measure of an exercise training effect. We found a 149% increase in CS
activity in the low intensity group compared to sedentary, a 425% difference between the
high intensity group compared to sedentary, and a 110% increase in activity of the high
intensity group compared to the low intensity group. These results indicate a clear dosedependent exercise training effect in the animals in this study.
When using citrate synthase activity as a marker of an exercise training effect it is
important that muscle samples are not harvested immediately following an exercise bout
as it has been demonstrated that citrate synthase activity is elevated following an acute
exercise bout (Leek et al., 2001). It is therefore necessary to allow the mice sufficient
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recovery between the last exercise bout and removal of the soleus muscle so the data are
not influenced by the final exercise bout. It is also important, however, to not wait too
long following the final exercise bout and muscle harvest as this could result in a
detraining effect. In this study we waited 72 hours following the final exercise bout to
harvest the soleus muscle as it appears from previous reports that this is a sufficient
period to allow citrate synthase activity to return to steady state following acute exercise
(Siu et al., 2003).
The increases in CS activity in this study in both exercise trained groups
compared to the sedentary group are greater than those of our previous study (Moore et
al., 2016) where we found a 39% increase in CS activity in the low intensity group
compared to sedentary and a 146% increase in CS activity in the high intensity group
compared to the sedentary group. A possible explanation for this is that the mice in the
previous study performed the exercise training program for three months whereas, the
mice in the current study exercise trained for 12 months. The absolute numbers for the
high and low intensity groups are not much different between the two studies, however,
with high intensity group CS means being 128 and 139 µmol min-1 g wet weight-1 for the
previous and current studies, respectively and the low intensity group CS means being 75
and 66 µmol min-1 g wet weight-1, respectively for the previous and current studies. The
sedentary groups differed by a fairly large margin between the studies (52 vs. 26 µmol
min-1 g wet weight-1, respectively for the previous and current studies) which is the
reason for the large percent difference between the studies in the low and high intensity
group comparisons to the sedentary group. The reason for the large difference between
sedentary group CS activity in these two studies is not readily apparent, although one
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possibility could be the age difference as citrate synthase activity has been reported to be
lower in gastrocnemius muscle of sedentary aged mice compared to sedentary young
mice (Ryan et al., 2010).
To date, the neuroscience community has not quantified the impact of physical
activity paradigms in the context of exercise training effects in studies investigating its
impact in reducing risk of pathology associated with neurodegenerative diseases. It is
highly likely that the intensity and/or volume of the physical activity conducted by an
individual is directly related to risk reduction of chronic neurological diseases such as
Alzheimer’s as this is the case with other chronic diseases, primarily cardiovascular
disease (Garber et al., 2011). In fact, this was demonstrated by our previous study (Moore
et al., 2016). For this reason it is important that future studies investigating the effect of
physical activity on reducing risk of neurological pathology assess the degree of a
training effect, or lack thereof, produced by the physical activity paradigm utilized in the
study.
Amyloid Plaque
Aβ deposition is a hallmark of AD pathogenesis. Aβ is normally present in the
ISF of the brain in soluble form throughout life (Cirrito et al., 2003). In AD pathology,
Aβ aggregates into toxic oligomers and eventually insoluble plaque in a concentration
dependent manner (Bero et al., 2011). Therefore, strategies, including physical activity,
aimed at reducing soluble Aβ in the brain prior to disease onset have been investigated as
a method of delaying the onset and slowing the progression of AD pathology.
In the previous study from our laboratory, Moore et al. (2016) demonstrated that
three months of exercise training in the form of treadmill running at two different
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intensities (15 m/min on a level grade and 32 m/min on a 10% grade for one hour per
day, five days per week) reduced ISF concentrations of soluble Aβ40 and Aβ42 in a dose
dependent manner in the cortex and hippocampus of young Tg2576 mice. It was further
demonstrated that a number of soluble Aβ clearance proteins were upregulated, the
degree of which was also exercise training dose-dependent, indicating that the lower
soluble Aβ levels were the result of increased Aβ clearance through multiple
mechanisms. These mechanisms included; 1) increased activity of Aβ degrading enzymes
NEP, IDE, and MMP-9, 2) upregulation of LRP1 increasing Aβ efflux from the brain
across the blood-brain barrier, and 3) upregulation of HSP-70 increasing Aβ stabilization
preventing aggregation. The work of Bero et al. (2011) suggests that if Tg2576 mice were
subjected to the same exercise training protocol as used by Moore et al. (2016) for a
prolonged period of time there should be a dose-dependent reduction in amyloid plaque
load later in life. The results of this study support that hypothesis as the percentage of the
area containing amyloid plaques in both the cortex and hippocampus of the mice used in
this study was significantly decreased in an exercise intensity dose-dependent manner.
Taken collectively, the results of this study and those of Moore et al. (2016) provide
support for the concept that brain amyloid plaque levels late in life are closely related to
soluble Aβ levels in early life and that strategies employed to keep ISF soluble Aβ levels
low early in life do, in fact, lead to reduced plaque levels in later life.
The data from this study provide clarification to previous studies into the effects
of physical activity interventions on amyloid plaque load in AD transgenic mice which
have been equivocal. Most studies have reported reduced amyloid plaque load as a result
of physical activity (Adlard et al., 2005; Lazarov et al., 2005; Um et al., 2008,2011;
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Yuede et al., 2009; Liu et al., 2013), however others have not found physical activity to
reduce amyloid plaque load (Cracchiolo et al., 2007). None of these previous studies have
considered the issue of the dose-dependence of exercise training on amyloid plaque
development. It is therefore, likely that the disparate results are due to differing
intensities of the physical activity paradigms employed in these studies. For this reason it
is recommended that all future studies investigating physical activity effects on reducing
AD pathology assess the exercise training impact using some objective measure such as
citrate synthase activity.
Another reason for differences among the studies mentioned above could be the
method used to deliver the physical activity as some studies utilized running wheels
(Adlard et al., 2005; Lazarov et al., 2005; Cracchiolo et al., 2007; Yuede et al., 2009) and
some used motor driven treadmills (Um et al., 2008,2011; Yuede et al., 2009; Liu et al.,
2013; Moore et al., 2016). It has been demonstrated that emotional stress accelerates
amyloid plaque development in Tg2576 mice (Dong et al., 2004, 2008) and argued that
treadmill running is not a good method of physical activity in studies using mice as it is
an emotionally stressful intervention (Yanagita et al., 2007). Wheel running, on the other
hand, is an activity that the mouse can perform at a time and intensity of its choosing and
thus has the advantage of not being emotionally stressful. On the other hand, exercise
training intensity cannot be controlled with running wheels as distance run on running
wheels is highly variable among animals and is of low intensity as it has been
demonstrated in rats that voluntary wheel running does not result in increased citrate
synthase activity compared to sedentary control animals even when the animals are
divided into high and low running groups (Nobel et al., 1999). A previous study from our

47

laboratory compared wheel running and treadmill running interventions in Tg 2576 mice
and found that plaque counts were lower in wheel running mice that treadmill trained
mice who ran at the same average speed as the wheel running mice. The running speed
was extremely low, however (average of 10.9 m/min on a level treadmill), which likely
did not produce an exercise training effect which unfortunately was not measured in that
study. In future studies, investigating exercise training as a strategy for delaying the onset
and slowing the progression of AD pathology it will be necessary to use treadmill
running to control exercise intensity and volume, both of which are important
contributors in AD risk reduction.
Behavioral Assessment
A prolonged forced exercise training may induce anxiety in mice which may
affect treadmill running (Svensson et al., 2016). The open field test, an indicator of
anxiety-like behavior, did not reveal any differences between the groups. This indicates
that 12 months of forced exercise training did not cause anxiety in the mice and therefore,
was unlikely to have an impact on the cognitive performance in the Morris Water Maze
(MWM) or Novel Object Recognition (NOR) tests. These data are consistent with reports
from Yuede et al. (2009) where forced treadmill exercise did not exhibit significant
anxiety-like behavior in the open field test.
In the MWM test the HI exercise trained group learned the location of the
platform faster than the LOW and SED groups as their latency to the platform in the
place trials significantly improved from day 1 to day 3 and continued to improve
throughout the five days. Analysis of simple main effects showed the performance of the
LOW group significantly improved from day 1 to day 4 and five while the SED group
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showed an indication of improved performance from day 1 to day 4 (day 1 to day 5
comparison was not significant). In the probe trial the latency to the platform location
was far less for the HI exercise trained group than the LOW and SED groups and the
latency to platform for the LOW group was significantly less than the SED group.
Significantly improved spatial memory function is also demonstrated in the HI group by
the increased time spent in the target quadrant relative to the LOW and SED groups.
Swimming speed was not different among groups demonstrating that it was not a factor
contributing to differences among groups in latency to platform during the place trial nor
latency to platform location during the probe trial. To further evaluate behavioral changes
resulting from the exercise training paradigms we subjected the mice to a NOR test to
assess recognition memory. As with the MWM test, the HI group performed significantly
better than LOW and SED, with the HI mice spending more time investigating the novel
object than the familiar object compared to the LOW and SED groups. The LOW and
SED groups did not differ in time spent investigating the novel and familiar objects.
Direct comparisons between our MWM and NOR data and those of others
studying transgenic AD mice subjected to exercise training treatments using treadmill
running are limited. Um et al. (2008) subjected NSE/APPsw mice who ran 13.2 m/min
on a level treadmill for 60 minutes a day, five days a week for 16 weeks and a sedentary
group to a MWM test. Their reported mean initial latency to the platform location times
in the probe trial for the sedentary and exercise trained groups were approximately 55 and
35 seconds, respectively (times estimated from Fig 3c in their manuscript). Interestingly,
these are very similar to the times for our SED (53.5 s) and LOW (39.9 s) groups. As for
NOR, the only direct comparison is to the study of Yuede et al. (2009) from our
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laboratory. In that study a group of Tg2576 mice subjected to treadmill running at an
average speed of 10.9 m/min on a level treadmill for 60 min/day, five days/week did not
differ from sedentary mice in preference for the novel object. This was also the case in
this study with the LOW to SED comparison. The data from this study are in agreement
with the previous studies with respect to behavior demonstrated in MWM and NOR
testing in AD transgenic mice subjected to low intensity treadmill running.
Taken collectively, our MWM and NOR data point to a clear dose-response of
Tg2576 mice to exercise training. In all cases, high intensity exercise training results in
significant, and dramatic, improvement in performance on both spatial and recognition
memory tasks compared to SED mice. Low intensity exercise training does improve
spatial memory over the sedentary condition as demonstrated by the improved latency to
the platform location in the probe trial of the MWM test indicating this treatment is
beneficial over the sedentary condition, however this difference is subtle.
The mechanisms through which the “stair-step” dose response effect of the
exercise training paradigm reduces amyloid plaque levels and improves cognitive
function remains unknown. Although mechanistic and signaling targets such as glucose
uptake, DNA repair, upregulation of neurogenic factors such as BDNF, increased levels
of clearance proteins, and upregulation of angiogenesis are a few of the processes that
may be modulated because of chronic physical activity, the mechanisms by which they
are modulated remains uninvestigated. One way to measure a dose response could be to
investigate cerebral blood flow. Although not consistently reported, increased cerebral
blood flow to the brain post exercise may lead to increased brain metabolism (Querido
and Sheel, 2007). Increased cerebral blood flow may also reduce the hypoxic condition of
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AD brains, as hypoxia facilitates AD pathogenesis by up-regulating BACE1 gene
expression (Sun et al, 2006), and may also modulate blood-brain barrier permeability,
regional brain glucose content, and local glucose utilization.
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SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS

In summary, these experiments have demonstrated that intensity and
duration of exercise training are important factors in dissecting the link between physical
activity and Alzheimer’s disease, and thus relevant to designing exercise training
paradigms. The exercise training interventions in this study helped to address the
beneficial effects of long-term treadmill exercise interventions in improving cognitive
function and decreasing amyloid-beta plaque levels in a dose-dependent manner in an AD
transgenic mouse model. More importantly, the dose response was quantified and
demonstrated by a metabolic assay which has been absent in previous studies in the field
of AD and neuroscience. The low intensity treadmill running protocol in this study was
more intense than the physical activity protocols in most of the previous studies
(summarized in Table 1). This indicates a likely minimum physical activity intensity
threshold below which the effect of the physical activity is not realized and suggests that
investigators in the future need to precisely assess physical activity levels in the study of
physical activity effects on AD pathology. Therefore, future study of physical activity
and exercise training effects on delaying the onset and slowing the progression of the
disease process in AD transgenic mouse models should utilize treadmill running to
precisely regulate exercise intensities and volume.
This study demonstrated the beneficial effects of a long-term (12-month)
treadmill exercise training regimen in cognitive improvement and amyloid plaque
reduction in 15-month old Tg2576 mice. Reports suggest that reducing soluble Aβ
concentrations subsequently reduces oligomerization and plaque levels in AD mouse
models as aging progresses. Even though physical activity has been used as an
52

intervention to reduce plaque levels and improve cognition in AD mouse models
(Parachikova et al., 2008), the prophylactic impact of exercise training at varying
intensities for a prolonged period in reducing amyloid plaque is not established. Moore et
al. (2016) demonstrated dose response reduction of soluble Aβ levels in the cortex and
hippocampus of 6-month old Tg2576 mice after 3 months of exercise training, starting at
3 months of age. They completed the exercise training regimen prior to amyloid plaque
development which is typically about nine months of age in Tg2576 mice. The current
study was a follow-up to the Moore study, utilizing the same experimental design but
with a long-term exercise training regimen.
For the first time, these experiments demonstrate that the intensity of exercise
training is imperative to elicit a dose response on cognitive performance and amyloid
plaque levels in an AD mouse model. An exercise training regimen in AD mouse models
becomes relevant for potential exercise interventions in AD patients. Whether exercise
training at varying intensities can be used as a preventative, treatment, or reversal
strategy against the pathogenesis of AD needs to be investigated in human patients. The
exercise training regimen in this study was for 12 months beginning before Aβ
oligomerization began. In human patients, the age at which Aβ aggregation begins is
difficult to detect. Firstly, novel techniques need to be developed to detect early levels of
Aβ before aggregation. Lastly, a quantified exercise training regimen needs to be
employed to elicit beneficial responses. Whether a long-term exercise training regimen
like the one used in this study could be beneficial in human AD patients is still
uninvestigated. In addition, the dose and duration of exercise intervention, and extent of
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beneficial effects post exercise intervention are important questions that need to be
addressed in the field of AD.
Furthermore, mechanistic pathways of physical activity in AD pathogenesis
remain cryptic. Exercise training interventions which are quantified could shed light into
APP processing, Aβ production, aggregation, and clearance in the brain. Understanding
the structural and molecular characteristics of different Aβ species and its interactions
with clearance/degradation molecules due to treadmill exercise may increase knowledge
of potential therapeutic targets. Additionally, utilizing mouse models with mutated APP
and altered clearance mechanisms could help define factors affecting the trafficking and
processing of Aβ.
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APPENDICES

Appendix A: Protocols

Appendix A-1. Tissue protein extraction from soleus muscles with CellLytic™ MT
and protein quantification with Pierce™ BCA protein assay kit.
Post isolation of left and right soleus muscle from the hind limbs of mice, the CellLytic
kit, catalog number C 3228, from Sigma Aldrich was utilized for tissue protein
extraction. Quantification of protein content in muscle was conducted through Pierce
BCA protein assay kit from Thermo Fisher Scientific, catalog number 23225.

Appendix A-2. NIH ImageJ analysis of amyloid plaques
Procedure
Mosaic images of Thioflavin-S stain
1. Procure mosaic images at 10X magnification on a Zeiss Axio Imager M1 under
identical exposure settings in the FITC channel
2. Equally threshold the images using the “Threshold” feature
3. For all representative mosaic images, set the boundaries of each individual brain
section including the hippocampus and cortex using the mosaic function
4. Obtain sequential images that encompasses the entire area of the tissue boundary
(between 25 and 50 images per section)
5. Stitch the individual images using the stitch function to produce a single image
Single images of DAB stain
1. Procure single images at 40X magnification on a Zeiss Axio Imager M1 under
identical exposure settings in the brightfield channel
2. Export the single images onto NIH ImageJ software
3. Indicate brain regions of interest using the “Pencil” feature
4. Quantify Aβ plaques in the cortex and hippocampus using the “Analyze Particles”
feature
5. Compare group means for the percentage of brain area measured
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Appendix A-3. Open Field Test
Procedure
1. Place mice in the center of a white box (l38.5xw30xh30 cm) and allow to move
freely for 10 min
2. Using Stoelting Anymaze software, measure the distance traveled and average
speed

Appendix A-4. Morris Water Maze Test
Procedure
Morris Water Maze testing was conducted in a 150 cm diameter pool divided into four
quadrants with the “goal quadrant” containing a submerged platform that the mice had to
find. Mice had a 7 day acquisition period with four 60 second trials per day. If the animal
did not find the platform within 60 seconds, lead it to the platform and allow to remain on
the platform for 30 seconds. All MWM trials were evaluated using ANY-maze video
tracking system (Stoelting Co., Wood Dale, IL).
I. Cued Trial
1. Conduct two days of cued trials in which a tennis ball denotes platform
location
2. Conduct four trials per cued day where the submerged platform is cycled
through each quadrant
3. Place mice in quadrant opposite to the goal quadrant in each of the trials
and record the time, distance, and speed covered
II. Acquisition Trial
1. Conduct acquisition trial for five consecutive days. For each of the
successive trails, place black shaped cues on the walls surrounding the
pool
2. Place the mice in a different quadrant using a random start pattern and
record the time, distance, and speed
III. Probe Trial
1. Conduct a single probe trial after a one hour delay following the last
acquisition trial. Remove the platform.
2. Place the mice in the quadrant opposite the goal quadrant and record the
time, distance, and speed
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Appendix A-5. Novel Object Recognition Test
Procedure
Mice were first acclimated to the test area for 20 minutes one day before testing
1. During the sample trial, place the mouse into the test arena for 10 minutes and
expose to two identical objects
2. After ten minutes, return the mouse to its home cage
3. After a 50 minute delay, introduce the mouse back into the test area for 10
minutes during the test trial with one of the objects from the sample trial and a
novel object
4. Record time spent investigating the objects for 10 minutes during the sample trial
and test trial using Stoelting Anymaze software

75

Appendix B: Raw Data

Appendix B-1. Body weight raw data (All values in grams).
Animal
#
Sedentary
Group

1
2
3
4

Months
3

4

5

6

7

8

9

10

11

12

13

14

15

17
19
17
18

18
19
18
20

20
21
19
21

22
22
20
24

23
23
22
25

25
25
22
26

26
26
23
28

28
28
24
28

28
29
24
29

29
31
26
29

31
32
27
30

31
34
30
32

33
35
31
32

19
16
16
16
18
14
15
15
18

19
17
17
17
20
15
16
16
20

22
18
19
19
19
16
18
16
21

23
20
21
19
18
18
20
17
21

25
21
22
22
18
19
22
17
25

26
23
24
20
18
22
22
19
25

26
24
24
22
21
23
24
22
26

28
26
26
22
21
25
26
23
27

28
27
27
22
21
25
26
25
28

30
28
28
24
22
26
27
25
28

32
30
29
24
25
27
28
26
29

34
31
29
28
26
27
30
26
30

35
31
30
30
29
28
31
28
32

14
13
16
17
15

16
15
15
19
17

18
15
17
20
18

19
16
20
23
23

19
18
23
25
23

23
21
25
24
25

26
21
25
26
26

27
23
24
27
25

27
24
24
27
27

29
25
27
28
29

31
25
28
29
31

32
28
31
30
33

34
30
31
30
33

Low
Intensity
Group

1
2
3
4
5
6
7
8
9
High
Intensity
Group

1
2
3
4
5
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Appendix B-2. Food intake raw data (values are in grams).

Animal #
Sedentary Group
1
2
3
4
Low Intensity Group
1
2
3
4
5
6
7
8
9
High Intensity Group
1
2
3
4
5
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Food Intake
2
4
3
3
2
2
4
3
2
4
4
2
3
3
2
3
2
4

Appendix B-3. Citrate synthase activity raw data (values are in µmoles/min g wet weight).

Animal #
Sedentary Group
1
2
3
4
Low Intensity Group
1
2
3
4
5
6
7
8
9
High Intensity Group
1
2
3
4
5
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CS Activity
24.44023
27.97466
26.06958
28
88.79949
68.84706
81.92579
70.06199
35.19393
55.61629
42.82353
96.07964
56.73935
146.1271
144.478
138.4242
132.1587
137.4479

Appendix B-4. Amyloid plaque % area.

Animal #
Sedentary Group
1
2
3
4
5
6
Low Intensity Group
1
2
3
4
5
6
High Intensity Group
1
2
3
4
5

Cortex

Hippocampus

0.380000
0.300000
0.467000
0.525500
0.487000
0.304000

0.584000
0.393500
0.303000
0.333500
0.377000
0.446000

0.280500
0.311000
0.258500
0.328000
0.297500
0.367000

0.249000
0.205000
0.291000
0.213000
0.247000
0.221000

0.1810
0.1250
0.1165
0.1800
0.1910

0.0860
0.0000
0.0260
0.0975
0.0040
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Appendix B-5. Open field test raw data (distance covered in area units).

Animal #
Sedentary Group
1
2
3
4
Low Intensity Group
1
2
3
4
5
6
7
8
9
High Intensity Group
1
2
3
4
5

Total distance

Middle field distance

0.284
0.154
0.21
0.177

0.056
0.013
0.052
0.017

0.222
0.186
0.2
0.196
0.181
0.176
0.171
0.167
0.158

0.015
0
0.021
0.035
0.045
0.051
0.014
0.031
0.025

0.162
0.157
0.252
0.147
0.242

0.037
0.013
0.117
0.101
0.117
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Appendix B-6. Morris water maze acquisition phase time to platform raw data (values are
in seconds).

Animal #
Sedentary Group
1
2
3
4
5
Low Intensity
Group
1
2
3
4
5
6
7
8
9
10
High Intensity
Group
1
2
3
4
5
6

Day 1
28.75
58.25
35.25
25.75
48
54.5

Day 2
22.5
49.25
34.75
25
22.75
60

Day 3
21.75
45.25
25.5
24.5
22.5
52.25

Day 4
22.25
37.5
30
20.75
23.25
47

Day 5
23.75
36
31.5
24.25
26.5
39.5

48.75
50.25
25.25
24.75
60
48
60
17.5
31.5
28.5

45.5
60
29.5
16.25
59.75
34.5
46.25
15.25
17
27

30.25
60
33
19.75
60
30.25
40
9
25.75
31.5

17.25
51.25
32
7.75
60
16.5
32
9
9.75
28.5

19.75
60
28.75
18.75
44.25
21.25
27
13.25
6.25
44.75

35.25
14
27.75
25.5
36.5
44.5

24
6.5
14
19.5
30.75
36.25

23
6.5
12.25
9
22.25
8

23.75
6.25
6
8.25
10.75
7.75

9.75
4.25
4.5
6.5
6
7.75
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Appendix B-7. Morris water maze probe trial raw data.

Animal #
Sedentary
Group
1
2
3
4
5
6
Low Intensity
Group
1
2
3
4
5
6
7
8
9
10
High Intensity
Group
1
2
3
4
5
6

Time in target
quadrant (s)

Latency to
platform (s)

Distance
traveled (m)

Avg. swimming
speed (m/s)

6
4.9
19.1
7.8
8.17
0

48.8
39.2
54
60
59
60

13.974
7.403
14.837
9.67
8.6
11.4

0.233
0.123
0.247
0.161
0.145
0.133

24.2
12
12.6
13.8
13.9
4.6
6.4
10.63
5.44
14.9

39.4
45.4
38.2
52.6
32.1
60
60
30.9
36
49

14.372
11.023
11.171
9.029
11.099
13.065
9.554
9.002
10.59
7.587

0.24
0.184
0.186
0.151
0.185
0.218
0.159
0.159
0.146
0.184

41.2
28.2
22.5
38.2
20.35
36.1

5
8.4
5
6.2
7
3

13.138
14.138
13.642
13.225
13.645
14.118

0.219
0.236
0.227
0.22
0.236
0.287
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Appendix B-8. Novel objection recognition test raw data (values are investigation times in
seconds).

Animal #
Sedentary Group
1
2
3
4
5
6
7
8
9
Low Intensity Group
1
2
3
4
5
6
7
8
9
10
11
12
High Intensity Group
1
2
3
4
5
6
7

Right side

Left side

Novel

Familiar

130
95
10
106
17
30
184
59
200

132
123
13
105
15
17
189
112
175

103
65
67
59
17
37
83
18
120

111
157
121
55
27
37
140
53
126

3
129
59
12
14
3
11
190
61
26
8
25

4
217
67
11
20
7
18
170
51
34
9
56

72
115
48
52
32
4
152
165
70
34
79
24

85
135
78
91
74
6
133
191
96
46
95
69

167
122
130
9
101
167
76

220
125
158
15
132
187
67

153
267
180
25
83
11
169

110
143
112
6
24
5
38
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Appendix B-9. Novel objection recognition test raw data (values are percent of
investigation time).

Animal #
Sedentary Group
1
2
3
4
5
6
7
8
9
Low Intensity Group
1
2
3
4
5
6
7
8
9
10
11
12
High Intensity
Group
1
2
3
4
5
6
7

Right side

Left side

Novel

Familiar

49.6
43.6
43.5
50.2
53.1
63.8
49.3
34.5
53.3

50.4
56.4
56.5
49.8
46.9
36.2
50.7
65.5
46.7

48.1
29.2
35.6
51.8
38.6
50.0
37.2
25.3
48.9

51.9
70.8
64.4
48.2
61.4
50.0
62.8
74.7
51.1

42.9
37.3
46.8
52.2
41.2
30
37.9
51.4
54.5
43.3
47.1
30.9

57.1
62.7
53.2
47.8
58.8
70
62.1
48.6
45.5
56.7
52.9
69.1

45.9
46.0
38.1
36.4
30.2
40.0
53.3
46.3
42.3
42.5
45.4
25.8

54.1
54.0
61.9
63.6
69.8
60.0
46.7
53.7
57.7
57.5
54.6
74.2

43.2
49.4
45.1
37.5
43.3
47.2
53.1

56.8
50.6
54.9
62.5
56.7
52.8
46.9

58.2
65.1
61.6
80.6
77.6
68.8
81.6

41.8
34.9
38.4
19.4
22.4
31.2
18.4
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